Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), is on a mission to eliminate OSA using its revolutionary Vivos System(R), a clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. An article discussing the company reads, “Designed to promote correct growth and development of the hard and soft tissues surrounding and compromising the oral cavity, nasal cavity, upper and lower jaws, and other tissues that comprise and shape the human airway. The system uses Pneumopedics(R), the natural process induced by Vivos biomimetic technology to widen and expand the patient’s airway, allowing for proper breathing through the nose, effectively addressing the root cause of OSA. . . . This patented technology offers benefits over CPAP and other oral appliances in its ability to achieve results relatively quickly — in about 18 to 24 months or less — at a lower cost, and without the need for lifetime intervention in most patients. It is believed to be the first effective, nonsurgical, noninvasive and potentially long-lasting solution to eradicating OSA.”
To view the full article, visit http://ibn.fm/AHJn1
About Vivos Therapeutics Inc.
Vivos Therapeutics is an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), a debilitating condition affecting nearly 1 billion people worldwide. Headquartered in Denver, Colorado, the company utilizes proprietary, groundbreaking technology; a proven, go-to-market strategy; and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep. At the core of Vivos’ mission to eradicate OSA is the Vivos System(R), a revolutionary clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. The Vivos System(R) multidisciplinary treatment protocol involves collaboration between physicians, specially trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health-care providers. In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the United States, Canada and Asia. For more information, visit the company’s website at www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.